WO 2005/002540 PCT/IB2004/002190

## WE CLAIM:

1

1

1

2

3

1

2

3

4

5

6

1 A dry powder pharmaceutical suspension composition suitable for use as a 2 liquid suspension, the composition comprising granules that include cefuroxime axetil, at 3 least one lubricant, and at least one glidant.

- 1 2. The composition of claim 1 wherein the composition exhibits better 2 bioavailability as compared to Ceftin® oral suspension.
- 3. 1 The composition of claim 1 wherein the composition is free of food effects.
- 1 4. The composition of claim 1 wherein the cefuroxime axetil comprises up to 2 about 99.89% by weight of the granules.
- 1 5. The composition of claim 1 wherein the lubricant comprises one or more of 2 stearic acid, calcium stearate, sodium stearyl fumarate and combinations thereof.
- 6. The composition of claim 1 wherein the lubricant comprises from about 2 0.01% to about 10% by weight of the granules.
- 1 7. The composition of claim 1 wherein the glidant comprises one or more of 2 colloidal silicon dioxide and talc.
- 8. The composition of claim 1 wherein the glidant comprises about 0.1% to 2 about 5% by weight of the granules.
  - The composition of claim 1 wherein the composition further comprises one 9. or more of suspending agents/viscosity enhancers, buffering agents, fillers, wetting agents, preservatives, flavouring agents, and sweeteners.
  - 10. The composition of claim 9 wherein the suspending agent/viscosity enhancer comprises one or more of cellulosic derivatives, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, sodium carboxymethylcellulose, gums, xanthan gum, guar gum; polysaccharides, starch, pregelatinised starch, alginates, sodium alginate; acrylic acid copolymers, carbopols, polyvinylpyrrolidone, and combinations thereof.
- 1 11. The composition of claim 9 wherein the buffering agent comprises one or 2 more of monosodium citrate, sodium citrate, citric acid, and combinations thereof.
- 1 The composition of claim 9 wherein the filler comprises one or more of 12. 2 sucrose, starch, lactose, microcrystalline cellulose, and combinations thereof.

**WO** 2005/002540 PCT/IB2004/002190

The composition of claim 9 wherein the wetting agent comprises one or 13. 2 more of sodium lauryl sulphate, polysorbates, tween 40, tween 60, tween 80, poloxamer, 3 and combinations thereof.

1

1

2

1

2

3

4

1

2

3

4

5

6

2

3

4

- The composition of claim 9 wherein the preservative comprises one or 14. more of methyl paraben, propyl paraben, sodium benzoate, and combinations thereof.
- 1 15. The composition of claim 9 wherein the flavouring agents/sweeteners comprise one or more of grenadine flavour, tutti frutti flavour, peppermint flavour, 2 3 aspartame, saccharine sodium, sucrose, sorbitol, sodium cyclamate and combinations 4 thereof.
  - 16. The composition of claim 1 wherein the granules comprise up to approximately 315 mg of cefuroxime axetil per 5 ml of suspension, up to approximately 6 mg of colloidal silicon dioxide per 5 ml of suspension, and up to approximately 6 mg of stearic acid per 5 ml of suspension.
  - 17. The composition of claim 9 wherein the composition comprises approximately 3979 mg of sucrose per 5 ml of suspension, approximately 20 mg of aspartame per 5 ml of suspension, approximately 84 mg of silicon dioxide per 5 ml of suspension, approximately 10 mg of monosodium citrate per 5 ml of suspension, approximately 19 mg of flavour per 5 ml of suspension, and approximately 10 mg of sodium chloride per 5 ml of suspension.
  - A process of forming a dry powder pharmaceutical suspension composition 18. suitable for use as a liquid suspension, the process comprising forming granules by granulating a mixture of cefuroxime axetil, at least one lubricant, and at least one glidant by compaction/slugging.
- 1 19. The process of claim 18 further comprising sizing the granules.
- 1 20. The process of claim 18 wherein the granules are prepared by compaction.
- 21. The process of claim 18 wherein the cefuroxime axetil comprises up to 2 about 99.89% by weight of the granules.
- 1 The process of claim 18 wherein the lubricant comprises one or more of 22. 2 stearic acid, calcium stearate, sodium stearyl fumarate, and combinations thereof.

WO 2005/002540 PCT/IB2004/002190

1 The process of claim 18 wherein the lubricant comprises from about 0.01% 23. 2 to about 10% by weight of the granules.

- 1 The process of claim 18 wherein the glidant comprises one or more of 24. 2 colloidal silicon dioxide and talc.
- 1 25. The process of claim 18 wherein the glidant comprises from about 0.1% to 2 about 5% by weight of the granules.
- 1 The process of claim 18 further comprises mixing one or more additional 26. 2 pharmaceutical excipients with the granules.
- 1 27. The process according to claim 25 wherein the additional pharmaceutical 2 excipients comprise one or more of suspending agents/viscosity enhancers, buffering 3 agents, fillers, wetting agents, preservatives, flavouring agents and sweeteners.

1

A method of dosing for infections treated with cefuroxime axetil, the 28. 2 method comprising administering a dry powder pharmaceutical suspension composition of 3 cefuroxime axetil dissolved or suspended in an ingestible liquid, the composition comprising granules that include cefuroxime axetil, at least one lubricant, and at least one 4 5 glidant.